AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
22 Mai 2008 - 1:00PM
PR Newswire (US)
PHILLIPSBURG, N.J., May 22 /PRNewswire-FirstCall/ -- Celldex
Therapeutics (a wholly-owned subsidiary of AVANT
Immunotherapeutics)(NASDAQ:AVAN) announced today that its lead
product candidate, CDX-110, being developed for the treatment of
Glioblastoma Multiforme (GBM), will be the subject of an oral
presentation at the 44th Annual Meeting of the American Society of
Clinical Oncology (ASCO). The ASCO meeting will be held at
McCormick Place in Chicago from May 30 through June 3, 2008. The
oral presentation, scheduled for Monday, June 2 from 10:00 - 10:15
a.m. CDT in room S406 (Vista Room), will include median survival
data from ACTIVATE, a phase IIa clinical trial, and data from ACT
II, the extension arm of the study. The presentation will be given
by John H. Sampson, MD, PhD, Associate Professor of Neurosurgery at
Duke University Medical Center. On April 16, 2008, Pfizer, Inc. and
Celldex entered into an agreement that granted Pfizer an exclusive
worldwide license to CDX-110, an investigational vaccine currently
in development for the treatment of GBM. About CDX-110 CDX-110 is
designed to induce or enhance the body's immune responses against
epidermal growth factor variant III (EGFRvIII) and may lead to
destruction of tumor cells that express this variant receptor. A
randomized Phase 2 trial is currently enrolling at 24 sites across
the United States. About Glioblastoma Multiforme GBM is the most
common form of primary brain tumor. It is an aggressive tumor with
very poor prognosis.(1) There are an estimated 10,000 new cases of
GBM annually in the United States, which predominantly affects
adults aged 45 to 70. Current GBM treatment options include
surgical resection, radiotherapy and chemotherapy. (1) Uddin S,
Jarmi T. Glioblastoma Multiforme. Available at
http://www.emedicine.com/NEURO/topic147.htm. Accessed May 6, 2008.
About AVANT Immunotherapeutics, Inc. AVANT Immunotherapeutics and
Celldex Therapeutics combined during the first quarter of 2008.
AVANT is a NASDAQ-listed company discovering and developing
innovative vaccines and targeted immunotherapeutics for the
treatment of cancer, infectious and inflammatory diseases. AVANT
focuses on the use of tumor-specific targets and human monoclonal
antibodies (mAbs) to precisely deliver therapeutic agents through
its novel "targeted immunization" approach. In addition, AVANT is
exploiting its access to proprietary human antibody technology for
development of therapeutic monoclonal antibodies (mAbs). AVANT's
deep product pipeline consists of products in varying stages of
development. Identification of the potential of EGFRvIII in cancer
diagnosis, prevention and therapy was based on the collaborative
efforts of Dr. Bert Vogelstein and Dr. Albert Wong at Johns Hopkins
University and Dr. Darell Bigner at Duke University. Application of
this discovery toward the development of the CDX-110 vaccine was
further advanced by Dr. John Sampson and his colleagues at the Duke
University Brain Tumor Center in collaboration with Dr. Amy
Heimberger at the MD Anderson Cancer Center. AVANT also has several
product candidates in its development pipeline including: --
CDX-1307, a product based on its proprietary APC Targeting
Technology(TM), which is in two Phase 1 clinical trials for
patients with advanced pancreatic, bladder, breast and colon
cancer; -- TP10, a complement inhibitor, in development for
transplantation and other indications; and -- Three candidates
based on oral, rapidly-protecting, single-dose and
temperature-stable vaccine technology, including combination
vaccines for travellers, the military and global health needs.
AVANT has three commercialized products, including Rotarix(R)
(partnered with GSK) for the prevention of rotavirus infection and
two human food safety vaccines for reducing salmonella infection in
chickens and eggs. Additional information on AVANT
Immunotherapeutics, Inc. can be obtained through its web site
http://www.avantimmune.com/. Contact: Marissa Nelson BMC
Communications +1-212-477-9007 x21 DATASOURCE: AVANT
Immunotherapeutics, Inc. CONTACT: Marissa Nelson of BMC
Communications for AVANT Immunotherapeutics, Inc., +1-212-477-9007
x21 Web site: http://www.avantimmune.com/
http://www.asco.org/ASCO/Meetings/ASCO+Annual+Meeting
Copyright
Avant Immunotherapeutics (MM) (NASDAQ:AVAN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Avant Immunotherapeutics (MM) (NASDAQ:AVAN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Avant Immunotherapeutics (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Avant Immunotherapeutics (MM)